Lee's Pharmaceutical Holdings Limited announced that, on 21 October 2022, Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke Hefei"), a wholly-owned subsidiary of the Company, has completed the patient enrolment for a Phase III, multicenter, randomised, double blinded, parallel-group clinical trial of Intrarosa, a product licensed from Endoceutics Inc. ("Endoceutics"), in the treatment of vulvovaginal atrophy ("VVA"). The clinical trial approval was granted to Zhaoke Hefei by the China's National Medical Products Administration on 5 January 2021. The study is led by Professor Long Sui from the Obstetrics and Gynecology Hospital of Fudan University.

Total of 418 patients has been enrolled by 28 study sites and the topline data is expected to be obtained by March 2023. Intrarosa is the only FDA and EMA approved, locally administered, daily non-estrogen steroid for the treatment of moderate to severe dyspareunia (pain during intercourse), a symptom of VVA, due to menopause. Intrarosa's product information does not have any boxed (safety) warnings, contrary to all other FDA approved drugs for the treatment of VVA, which have boxed warnings.

Intrarosa contains prasterone, also known as dehydroepiandrosterone (DHEA). Prasterone is an inactive endogenous steroid, which is converted locally into androgens and estrogens to help restore the vaginal tissue as indicated by improvements in the percentage of superficial and parabasal cells, and pH.